Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

SV Health Investors

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 301
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 165
Rounds per year 10.38
Lead investments 48
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.45
Exits 75
Key employees 7
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Medical
  • Therapeutics
Summary

SV Health Investors appeared to be the VC, which was created in 1993. The main office of represented VC is situated in the Boston. The venture was found in North America in United States.

We can highlight the next thriving fund investment areas, such as Biopharma, Medical. Among the most popular portfolio startups of the fund, we may highlight EBR Systems, AcuFocus, Schweiger Dermatology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The overall number of key employees were 7.

When the investment is from SV Health Investors the average startup value is 10-50 millions dollars. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. Comparing to the other companies, this SV Health Investors performs on 12 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the SV Health Investors, startups are often financed by Split Rock Partners, Polaris Partners, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are Split Rock Partners, Novartis Venture Fund, DeNovo Ventures. In the next rounds fund is usually obtained by OrbiMed, Novo Holdings, Clarus Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of SV Health Investors:
Typical Co-investors
SV Health Investors is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after SV Health Investors:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nimbus Therapeutics

Alternative Medicine
Biotechnology
Health Care
Therapeutics
$125M12 Sep 2022 Cambridge, Massachusetts, United States

Ria Health

Health Care
Medical
mHealth
$18M29 Jun 2022 San Francisco, California, United States

Vittoria Biotherapeutics

Bioinformatics
Biotechnology
Test and Measurement
$10M07 Jun 2022 Philadelphia, Pennsylvania, United States

TRex Bio

Bioinformatics
Biopharma
Biotechnology
$26M08 Mar 2022 South San Francisco, California, United States

Rondo Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
$67M02 Mar 2022 Hayward, California, United States

Eyebiotech

Biotechnology
Medical
$65M22 Feb 2022 New York, New York, United States

Perfuze

Biotechnology
Health Care
Medical
Medical Device
$26M09 Feb 2022 Galway City, County Galway, Ireland

Quell Therapeutics

Association
Biotechnology
Education
$156M29 Nov 2021 London, England, United Kingdom

Alpheus Medical

Biotechnology
Health Diagnostics
$16M17 Nov 2021 Oakdale, Pennsylvania, United States
News
Zerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions

– Zerigo Health announced a $43m Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer.
– The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital.
– This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.
– Glen Tullman, Managing Partner of 7wireVentures, former Founder and CEO of Livongo, and Chief Executive Officer of Transcarent, will join as Executive Chairman of the company’s Board of Directors.

TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases

– TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59m Series A financing.
– Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
– Investors include Eli Lilly and Company, SV Health, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.
– TRexBio also announced the appointment of Johnston Erwin as Chief Executive Officer, and Ovid Trifan, M.D., Ph.D., as Chief Medical Officer, as part of the company’s plan to accelerate growth.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent SV Health Investors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: